购物车
- 全部删除
- 您的购物车当前为空
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。
为众多的药物研发团队赋能,
让新药发现更简单!
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 136 | 现货 | |
5 mg | ¥ 313 | 现货 | |
10 mg | ¥ 493 | 现货 | |
25 mg | ¥ 893 | 现货 | |
50 mg | ¥ 1,430 | 现货 | |
100 mg | ¥ 2,290 | 现货 | |
200 mg | ¥ 3,280 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 318 | 现货 |
产品描述 | AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3, and c-Kit. |
靶点活性 | FLT3:7 nM, c-Kit:9 nM, PDGFRβ:4 nM, VEGFR2:8 nM |
体外活性 | 在C6大鼠胶质瘤模型中,口服AZD2932 (12.5 or 50 mg/kg, b.i.d.)能够抑制肿瘤生长.在带有非PDGFβ表达肿瘤细胞的异种移植物中,口服AZD2932 (50 mg/kg, b.i.d.),Calu-6肿瘤和LoVo肿瘤达生长被抑制. |
体内活性 | AZD2932能够抑制PDGFRα和PDGFRβ磷酸化。AZD2932有效抑制多种受体,如VEGFR-2(IC50=8 nM),PDGFRβ(IC50=4 nM),Flt-3(IC50=7 nM)和c-Kit(IC50=9 nM)的活性。 |
激酶实验 | Kinase Assays : In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology. |
分子量 | 447.49 |
分子式 | C24H25N5O4 |
CAS No. | 883986-34-3 |
Smiles | COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(c4)C(C)C)cc3)c2cc1OC |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 82 mg/mL (183.2 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 5 mg/mL (11.17 mM), Heating is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容